Apellis falls on EMA's negative opinion of eye drug

Apellis Pharmaceuticals

26/01/2024 12:57

** Shares of drugmaker Apellis Pharmaceuticals  APLS.O  fall
~1.2% to $65.49 premarket
    ** The European Medicines Agency (EMA) has recommended the
refusal of marketing authorization for Apellis' eye disease drug
Syfovre
    ** EMA says that the benefits of treatment should impact
patients' everyday functioning, and this was not demonstrated in
the studies for Syfovre
    ** Adds, the benefits of the drug did not outweigh its risks
    ** APLS plans to seek immediate re-examination of its
marketing application
    ** As of last close, stock up 25.5% in the last 12 months

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))